Activity Details

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

• Recognize that patients with CTD are at increased risk for developing PAH.
• Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
• Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
• Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
• Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

• Read the learning objectives and faculty disclosures
• Complete the pre-test
• Study the educational activity
• Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Activity Details

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

• Recognize that patients with CTD are at increased risk for developing PAH.
• Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
• Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
• Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
• Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

• Read the learning objectives and faculty disclosures
• Complete the pre-test
• Study the educational activity
• Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

• Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
• Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
• Review treatment options based on clinical evidence and expert guidelines.
• Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.

Activity Description

In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.

Statement of Educational Need

Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.

Agenda

Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty

Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland

Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty

Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland

Activity Chair

Elizabeth R. Volkmann, MD, MS
Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon

Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim

Kristin B. Highland, MD, MSCR
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

• Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
• Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
• Review treatment options based on clinical evidence and expert guidelines.
• Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.

Activity Description

In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.

Statement of Educational Need

Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.

Agenda

Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty

Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland

Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty

Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland

Activity Chair

Elizabeth R. Volkmann, MD, MS
Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon

Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim

Kristin B. Highland, MD, MSCR
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, pulmonologists, and other clinicians involved in the management of patients with pediatric asthma.

Statement of Need

Currently, more than 5.5 million children (age <18 years) in the United States have been diagnosed with asthma.¹ An estimated 5% of this pediatric population suffer from severe asthma—disease that necessitates treatment with high-dose inhaled corticosteroids (ICS) plus a second controller and/or oral corticosteroids (OCS) to retain control, or which remains uncontrolled despite this therapy.^2,3 These children are at a heightened risk of death from recurrent, life-threatening asthma exacerbations, increased morbidity, impaired lung function, and reduced health-related quality of life.^4-7 Asthma is the leading cause of emergency department visits and among the top 3 reasons children are hospitalized.8 Therefore, there is great urgency not only to prevent the detrimental effects of asthma but to implement timely and effective treatment plans for the management of these young patients.

During this Engaging the Patient™ program, two asthma specialists will share their interpretive insights on the characteristics of pediatric asthma, its underlying pathophysiology, and the rationale for targeted biologic therapies. Faculty will share clinical trial evidence for the use of newer biologic therapies within this pediatric population and detail the positioning of biologics within recently published guidelines. Interactive faculty discussions surrounding the management of young patients with severe asthma as well as key elements for shared decision-making will be included throughout the program, supporting the translation of information to practice. Lastly, prerecorded video vignettes of a parent’s testimonial and follow-up office visit will provide real-life perspectives on the immense burden of disease and the impact asthma has on patients and their families.

References

1. Centers for Disease Control and Prevention. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. Accessed April 14, 2021.
2. Chung KF, et al. Eur Respir J. 2014;43(2):343-373.
3. Lang DM. Allergy Asthma Proc. 2015;36(6):418-424.
4. Moorman JE, et al.Vital Health Stat 3. 2012(35):1-58.
5. Sullivan SD, et al. Allergy. 2007;62(2):126-133.
6. Strine TW, et al. Chest. 2004;126(6):1849-1854.
7. Müllerová H, et al. J Asthma. 2020;1-12.
8. American Lung Association. www.lung.org/lung-health-diseases/lung-disease-lookup/asthma/learn-about-asthma/asthma-children-facts-sheet#:~:text=In%202016%2C%203%2C651%20deaths%20were,adults%20over%2085%20years%20old. Accessed April 14, 2021.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

1. Discuss pathophysiologic inflammatory processes in pediatric asthma that support phenotypic classification, risk stratification, and targeted treatment
2. Longitudinally evaluate pediatric patients with asthma for disease severity, symptom control, lung function, and disease phenotypes
3. Describe the clinical profiles and evidence for current and emerging biologic treatment options for pediatric asthma
4. Construct individualized treatment regimens for pediatric patients with moderate-to-severe asthma based on symptoms, comorbidities, and shared clinical decision-making

Faculty

Mario Castro, MD, MPH
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers: University of Kansas Clinical and Translational Science Institute
Director, Rainbow Clinical Trials Science Unit
University of Kansas Medical Center
Kansas City, Kansas

Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Clinical Research Center
Division of Asthma, Allergy, Dermatology, Rheumatology, and Immunology
Boston Children’s Hospital
Boston, Massachusetts

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the post-test and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mario Castro, MD, MPH
Consultant: Genentech, Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceuticals USA, Inc.;
Contracted Research: AstraZeneca, GlaxoSmithKline plc, Novartis International AG, Pulmatrix, Inc., Sanofi S.A., Shionogi Inc.;
Honoraria: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.;
Speakers Bureau: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.

Wanda Phipatanakul, MD, MS
Consultant: Genentech, Inc., GlaxoSmithKline plc, Novartis International AG, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, pulmonologists, and other clinicians involved in the management of patients with pediatric asthma.

Statement of Need

Currently, more than 5.5 million children (age <18 years) in the United States have been diagnosed with asthma.¹ An estimated 5% of this pediatric population suffer from severe asthma—disease that necessitates treatment with high-dose inhaled corticosteroids (ICS) plus a second controller and/or oral corticosteroids (OCS) to retain control, or which remains uncontrolled despite this therapy.^2,3 These children are at a heightened risk of death from recurrent, life-threatening asthma exacerbations, increased morbidity, impaired lung function, and reduced health-related quality of life.^4-7 Asthma is the leading cause of emergency department visits and among the top 3 reasons children are hospitalized.8 Therefore, there is great urgency not only to prevent the detrimental effects of asthma but to implement timely and effective treatment plans for the management of these young patients.

During this Engaging the Patient™ program, two asthma specialists will share their interpretive insights on the characteristics of pediatric asthma, its underlying pathophysiology, and the rationale for targeted biologic therapies. Faculty will share clinical trial evidence for the use of newer biologic therapies within this pediatric population and detail the positioning of biologics within recently published guidelines. Interactive faculty discussions surrounding the management of young patients with severe asthma as well as key elements for shared decision-making will be included throughout the program, supporting the translation of information to practice. Lastly, prerecorded video vignettes of a parent’s testimonial and follow-up office visit will provide real-life perspectives on the immense burden of disease and the impact asthma has on patients and their families.

References

1. Centers for Disease Control and Prevention. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. Accessed April 14, 2021.
2. Chung KF, et al. Eur Respir J. 2014;43(2):343-373.
3. Lang DM. Allergy Asthma Proc. 2015;36(6):418-424.
4. Moorman JE, et al.Vital Health Stat 3. 2012(35):1-58.
5. Sullivan SD, et al. Allergy. 2007;62(2):126-133.
6. Strine TW, et al. Chest. 2004;126(6):1849-1854.
7. Müllerová H, et al. J Asthma. 2020;1-12.
8. American Lung Association. www.lung.org/lung-health-diseases/lung-disease-lookup/asthma/learn-about-asthma/asthma-children-facts-sheet#:~:text=In%202016%2C%203%2C651%20deaths%20were,adults%20over%2085%20years%20old. Accessed April 14, 2021.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

1. Discuss pathophysiologic inflammatory processes in pediatric asthma that support phenotypic classification, risk stratification, and targeted treatment
2. Longitudinally evaluate pediatric patients with asthma for disease severity, symptom control, lung function, and disease phenotypes
3. Describe the clinical profiles and evidence for current and emerging biologic treatment options for pediatric asthma
4. Construct individualized treatment regimens for pediatric patients with moderate-to-severe asthma based on symptoms, comorbidities, and shared clinical decision-making

Faculty

Mario Castro, MD, MPH
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers: University of Kansas Clinical and Translational Science Institute
Director, Rainbow Clinical Trials Science Unit
University of Kansas Medical Center
Kansas City, Kansas

Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Clinical Research Center
Division of Asthma, Allergy, Dermatology, Rheumatology, and Immunology
Boston Children’s Hospital
Boston, Massachusetts

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the post-test and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mario Castro, MD, MPH
Consultant: Genentech, Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceuticals USA, Inc.;
Contracted Research: AstraZeneca, GlaxoSmithKline plc, Novartis International AG, Pulmatrix, Inc., Sanofi S.A., Shionogi Inc.;
Honoraria: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.;
Speakers Bureau: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.

Wanda Phipatanakul, MD, MS
Consultant: Genentech, Inc., GlaxoSmithKline plc, Novartis International AG, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.^1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.^3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.⁶ Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.⁷

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
6. Moorman JE, et al.Vital Health Stat 3. 2012;35:1-58.
7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

• Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses
• Describe how to promote shared decision making with patients with moderate-to-severe asthma and caregivers using disease state education and open communication about treatment options

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California

Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 67% or better on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.^1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.^3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.⁶ Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.⁷

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
6. Moorman JE, et al.Vital Health Stat 3. 2012;35:1-58.
7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

• Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses
• Describe how to promote shared decision making with patients with moderate-to-severe asthma and caregivers using disease state education and open communication about treatment options

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California

Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 67% or better on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.